Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBIT (2016 - 2025)

Sunshine Biopharma's EBIT history spans 13 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, EBIT rose 12.16% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$6.2 million, down 8.05%, while the annual FY2025 figure was -$6.2 million, 7.14% down from the prior year.
  • EBIT reached -$1.8 million in Q4 2025 per SBFM's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$279631.0 in Q4 2021 to a low of -$23.4 million in Q4 2022.
  • Average EBIT over 5 years is -$2.3 million, with a median of -$1.2 million recorded in 2022.
  • Peak YoY movement for EBIT: plummeted 8255.16% in 2022, then skyrocketed 94.92% in 2023.
  • A 5-year view of EBIT shows it stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then surged by 94.92% to -$1.2 million in 2023, then plummeted by 71.64% to -$2.0 million in 2024, then rose by 12.16% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBIT are -$1.8 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.1 million (Q2 2025).